-transparent.png){kind=logo}
The effectiveness of a recently synthesized corticotropin releasing factor (CRF) antagonist, alpha-helical CRF9-41, in reversing the locomotor activating and proconflict effects of CRF was evaluated. The CRF receptor antagonist (50, 100 and 200 micrograms, i.c.v.) produced a dose-related attenuation of the response-suppressing effects of CRF in a conflict model of anxiety. The antagonist also effectively suppressed the marked locomotor activation produced by CRF. No discernible intrinsic effects on behavior were noted when the antagonist was administered alone. These results suggest that the behavioral effects of CRF are receptor-mediated phenomena and point to the potential usefulness of a CRF antagonist in understanding the function of endogenous CRF in mediating responses to stressful stimuli.
K T Britton, and
G Lee, and
W Vale, and
J Rivier, and
G F Koob
November 1984,
Pharmacology, biochemistry, and behavior,
K T Britton, and
G Lee, and
W Vale, and
J Rivier, and
G F Koob
May 2006,
Psychopharmacology,
K T Britton, and
G Lee, and
W Vale, and
J Rivier, and
G F Koob
October 1997,
Brain research,
K T Britton, and
G Lee, and
W Vale, and
J Rivier, and
G F Koob
September 1968,
Nihon Ishikai zasshi. Journal of the Japan Medical Association,
K T Britton, and
G Lee, and
W Vale, and
J Rivier, and
G F Koob
May 1987,
No shinkei geka. Neurological surgery,
K T Britton, and
G Lee, and
W Vale, and
J Rivier, and
G F Koob
July 1966,
Horumon to rinsho. Clinical endocrinology,
K T Britton, and
G Lee, and
W Vale, and
J Rivier, and
G F Koob
May 1969,
Nihon rinsho. Japanese journal of clinical medicine,
K T Britton, and
G Lee, and
W Vale, and
J Rivier, and
G F Koob
September 1976,
Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.),
K T Britton, and
G Lee, and
W Vale, and
J Rivier, and
G F Koob
January 1988,
Endocrinology,
K T Britton, and
G Lee, and
W Vale, and
J Rivier, and
G F Koob
December 1993,
Endocrinology,
